Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect

Tumor immunosurveillance in human cancers

(2011) Bernhard Mlecnik et al.   CANCER AND METASTASIS REVIEWS

Combination of Tetrandrine with cisplatin enhances cytotoxicity through growth suppression and apoptosis in ovarian cancer in vitro and in vivo

(2011) Yuxing Zhang et al.   CANCER LETTERS

Clinical Impact of Different Classes of Infiltrating T Cytotoxic and Helper Cells (Th1, Th2, Treg, Th17) in Patients with Colorectal Cancer

(2011) Marie Tosolini et al.   CANCER RESEARCH

Randomized Trial of Autologous Cellular Immunotherapy with Sipuleucel-T in Androgen-Dependent Prostate Cancer

(2011) T. M. Beer et al.   CLINICAL CANCER RESEARCH

Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity

(2011) Caroline Jochems et al.   EXPERIMENTAL BIOLOGY AND MEDICINE

PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion Vaccine

(2011) Jacalyn Rosenblatt et al.   JOURNAL OF IMMUNOTHERAPY

Molecular Mechanisms of Natural Killer Cell Activation

(2011) Yenan T. Bryceson et al.   Journal of Innate Immunity

The Bidirectional Crosstalk between Human Dendritic Cells and Natural Killer Cells

(2011) Rebekka Wehner et al.   Journal of Innate Immunity

Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study

(2010) S. J. O'Day et al.   ANNALS OF ONCOLOGY

Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment

(2010) Thomas F Gajewski et al.   CURRENT OPINION IN IMMUNOLOGY

Intratumoral T cell infiltration, MHC class I and STAT1 as biomarkers of good prognosis in colorectal cancer

(2010) J. A. D. Simpson et al.   GUT

Synergistic effects of CTLA-4 blockade with tremelimumab and elimination of regulatory T lymphocytes in vitro and in vivo

(2010) Natalia Suarez et al.   INTERNATIONAL JOURNAL OF CANCER

Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice

(2010) Rupal Ramakrishnan et al.   JOURNAL OF CLINICAL INVESTIGATION

Messenger RNA-based Vaccines With Dual Activity Induce Balanced TLR-7 Dependent Adaptive Immune Responses and Provide Antitumor Activity

(2010) Mariola Fotin-Mleczek et al.   JOURNAL OF IMMUNOTHERAPY

Unknown

(2010) Karoline Lipnik et al.   MOLECULAR MEDICINE

Exploiting cross-priming to generate protective CD8 T-cell immunity rapidly

(2010) N.-L. L. Pham et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Ipilimumab: Unleashing the Power of the Immune System Through CTLA-4 Blockade

(2010) Peter Boasberg et al.   SEMINARS IN ONCOLOGY

The Emerging Toxicity Profiles of Anti–CTLA-4 Antibodies Across Clinical Indications

(2010) Anna Maria Di Giacomo et al.   SEMINARS IN ONCOLOGY

Immune Checkpoint Proteins: A New Therapeutic Paradigm for Cancer—Preclinical Background: CTLA-4 and PD-1 Blockade

(2010) Jeffrey Weber   SEMINARS IN ONCOLOGY

Signaling Through OX40 Enhances Antitumor Immunity

(2010) Shawn M. Jensen et al.   SEMINARS IN ONCOLOGY

Clinical Significance of Tumor-Infiltrating Lymphocytes in Lung Neoplasms

(2009) Enrico Ruffini et al.   ANNALS OF THORACIC SURGERY

Coordination of Intratumoral Immune Reaction and Human Colorectal Cancer Recurrence

(2009) M. Camus et al.   CANCER RESEARCH

First-line chemotherapy of non-seminomatous germ cell tumors(NSGCTs)

(2009) K. Pliarchopoulou et al.   CANCER TREATMENT REVIEWS

MAGRIT: The Largest-Ever Phase III Lung Cancer Trial Aims to Establish a Novel Tumor-Specific Approach to Therapy

(2009) Preeta Tyagi et al.   Clinical Lung Cancer

Intraepithelial Effector (CD3+)/Regulatory (FoxP3+) T-Cell Ratio Predicts a Clinical Outcome of Human Colon Carcinoma

(2009) Frank A. Sinicrope et al.   GASTROENTEROLOGY

Phase II Study of Cisplatin Plus Etoposide and Bevacizumab for Previously Untreated, Extensive-Stage Small-Cell Lung Cancer: Eastern Cooperative Oncology Group Study E3501

(2009) Leora Horn et al.   JOURNAL OF CLINICAL ONCOLOGY

CD3+ cells at the invasive margin of deeply invading (pT3–T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study

(2009) Luigi Laghi et al.   LANCET ONCOLOGY

Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia

(2009) Gemma G. Kenter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined modality immunotherapy and chemotherapy: a new perspective

(2008) Rupal Ramakrishnan et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Cancer treatment: the combination of vaccination with other therapies

(2008) Mads Hald Andersen et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Combination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer

(2008) Tianqian Zhang et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Induction of Tumor-Specific CD4+ and CD8+ T-Cell Immunity in Cervical Cancer Patients by a Human Papillomavirus Type 16 E6 and E7 Long Peptides Vaccine

(2008) M. J.P. Welters et al.   CLINICAL CANCER RESEARCH

Combination of Docetaxel and Recombinant Vaccine Enhances T-Cell Responses and Antitumor Activity: Effects of Docetaxel on Immune Enhancement

(2008) C. T. Garnett et al.   CLINICAL CANCER RESEARCH

Pretreatment with Cisplatin Enhances E7-Specific CD8+ T-Cell-Mediated Antitumor Immunity Induced by DNA Vaccination

(2008) C.-W. Tseng et al.   CLINICAL CANCER RESEARCH

Chemotherapy for recurrent and metastatic cervical cancer

(2008) Xia Tao et al.   GYNECOLOGIC ONCOLOGY

Angiostatic immune reaction in colorectal carcinoma: Impact on survival and perspectives for antiangiogenic therapy

(2008) Elisabeth Naschberger et al.   INTERNATIONAL JOURNAL OF CANCER

Results of the First Phase I/II Clinical Vaccination Trial With Direct Injection of mRNA

(2008) Benjamin Weide et al.   JOURNAL OF IMMUNOTHERAPY

Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer

(2007) R. Rosell et al.   ANNALS OF ONCOLOGY